Eli Lilly & Co. raised its full-year sales forecast as demand for its blockbuster obesity and diabetes drugs continues to surge. Speaking on "Bloomberg Open Interest," Muller also discusses the implications for Novo Nordisk. (Source: Bloomberg)
CryptoAlerta — análise de criptomoedas e mercado em tempo real